You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Drug Sales Trends for GENTAMICIN


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for GENTAMICIN (2016)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $922,646
DRUG STORE $3,358,732
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 76,997
DRUG STORE 180,502
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $36,474
MEDICARE $719,056
[disabled in preview] $3,560,413
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for GENTAMICIN
Drug Units Sold Trends for GENTAMICIN

Annual Sales Revenues and Units Sold for GENTAMICIN

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2022
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2021
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2020
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2019
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2018
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2017
GENTAMICIN ⤷  Start Trial ⤷  Start Trial 2016
>Drug Name >Revenues (USD) >Units >Year

GENTAMICIN Market Analysis and Financial Projection

Last updated: February 14, 2026

What Is the Market Size for Gentamicin?

Gentamicin is an aminoglycoside antibiotic used primarily to treat serious bacterial infections. Its global market was valued at approximately $280 million in 2022, with an expected compound annual growth rate (CAGR) of 3.2% from 2023 to 2030. The growth is driven by increasing bacterial infection rates, expanding drug approvals, and the rising prevalence of antibiotic-resistant pathogens.

How Is the Market Segmented?

The market can be broken down across several dimensions:

  • Application: Respiratory tract infections, sepsis, urinary tract infections, skin infections, and intra-abdominal infections. Respiratory infections and sepsis account for roughly 40% and 25%, respectively, of total gentamicin sales.

  • Formulation: Injectable formulations dominate, with an estimated 85% of sales. Oral formulations are less common due to poor absorption.

  • End Users: Hospitals (majority of sales, 70%), clinics, and compounding pharmacies.

  • Geography:

    • North America: 40% of market share
    • Europe: 25%
    • Asia-Pacific: 20%
    • Rest of the World: 15%

Growth in Asia-Pacific is driven by increasing healthcare infrastructure and bacterial infection prevalence, with a CAGR projected at 4.5%.

What Are the Leading Companies and Their Market Shares?

Top players include:

Company Estimated Market Share (2022) Notable Attributes
Fresenius Kabi 35% Leading supplier in injectable antibiotics
Hikma Pharmaceuticals 20% Expanding distribution in emerging markets
Sandoz (Novartis) 15% Focus on pharmaceutical generics
Others 30% Including local manufacturers

Generic formulations dominate due to patent expirations dating back to the early 2000s.

What Are the Sales Projections?

Total global sales are projected to reach approximately $370 million by 2030, with a CAGR of 3.2%. Key drivers include:

  • Increased infections in aging populations.
  • Emergence of resistant bacteria, prompting continued use of aminoglycosides.
  • Expansion into emerging markets, where antibiotics are increasingly available.

Regional performance projections:

  • North America: CAGR of 2.8%
  • Europe: 3.0%
  • Asia-Pacific: 4.5%

Growth is tempered by rising concerns over nephrotoxicity and ototoxicity associated with gentamicin use, which may influence prescribing patterns.

What Regulatory and Market Trends Impact Gentamicin?

  • Antibiotic Stewardship: Stricter regulations and stewardship programs limit overuse.
  • Alternative Therapies: Development of new classes like aminoglycoside combinations or non-traditional antibiotics may reduce demand.
  • Biosimilars and Generics: Increased competition from biosimilars can lower prices.
  • Global Health Initiatives: Efforts to combat antimicrobial resistance may restrict usage in some regions.

Summary of Key Market Risks and Opportunities

Risks:

  • Rising toxicity concerns.
  • Stringent regulations affecting approval and distribution.
  • Competitive pressure from newer antibiotics or combination therapies.

Opportunities:

  • Growth in regions with increasing healthcare access.
  • Expanded indications and combination regimens.
  • Development of formulations with reduced toxicity profiles.

Key Takeaways

  • The global gentamicin market reached approximately $280 million in 2022.
  • Market growth is driven by increasing bacterial infections, aging populations, and emerging markets.
  • Generic formulations dominate due to expiration of patents.
  • The regional market grows fastest in Asia-Pacific, with a 4.5% CAGR.
  • Toxicity concerns and regulatory constraints pose ongoing risks, but emerging markets and new formulations offer growth potential.

FAQs

1. How does gentamicin compare to other aminoglycosides?
Gentamicin has a broad spectrum and is often preferred for gram-negative infections. It carries similar toxicity risks as tobramycin and amikacin but is typically less expensive.

2. Are there new formulations of gentamicin in development?
No major novel formulations are currently under development, but efforts focus on reducing toxicity through targeted delivery systems and combination therapies.

3. What factors influence gentamicin pricing?
Patent status, manufacturing costs, regional regulations, and market competition influence pricing. Generics are significantly cheaper than branded options.

4. How are resistance patterns affecting gentamicin use?
Rising resistance in certain bacteria reduces efficacy, prompting clinicians to use alternative treatments or combination therapies, which may influence demand.

5. What is the outlook for gentamicin in low-resource settings?
High affordability and established use make gentamicin a mainstay in low-resource settings, although toxicity and resistance are concerns.


Sources

[1] MarketWatch, "Gentamicin Market Size, Share & Industry Trends," 2023.
[2] Grand View Research, "Antibiotics Market Analysis," 2022.
[3] World Health Organization, "Antimicrobial Resistance," 2022.
[4] EvaluatePharma, "Pharmaceutical Sales Data," 2022.
[5] IQVIA, "Global Antibiotics Market Reports," 2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.